ArticleVaccines2022

Phase 3 Randomized, Multicenter, Placebo-Controlled Study to Evaluate Safety, Immunogenicity, and Lot-to-Lot Consistency of an Adjuvanted Cell Culture-Derived, H5N1 Subunit Influenza Virus Vaccine in Healthy Adult Subjects.

James Peterson et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.